Aeroponics Integrated Systems has entered into an independent research agreement with Dr. Robb Farms to conduct a third-party verification trial of its next-generation aeroponics technology.
Under the terms of the agreement, Dr. Robert Flannery, Dr. Robb Farms CEO, will serve as study director and principal investigator. "Known as the first PhD of pot, Dr. Flannery is among the cannabis industry’s leading plant scientists," the team with the company explains. "The intent of the study is to provide independent verification of the increased yield and reduced water usage claims made by AIS in association with its aeroponics cultivation system."
AIS CEO Steve Crane says, “Our patent-pending aeroponics cultivation technology is the result of nearly 30 years of hands-on development in cannabis cultivation by our co-founder. We have historically averaged 4lbs of ultra-high quality, dried, cured and hand-trimmed flower per light, while using 40% less water than hydroponics. We fully expect to meet or exceed those statistics in the trial with Dr. Robb Farms.”
“I have grown cannabis in every conceivable medium and process, and have considerable experience with aeroponics. When I learned of the AeroBloom system, I was eager to document its performance at our research and development facility. Obviously, if it performs as advertised it could represent a new paradigm in indoor cannabis cultivation, a potentially disruptive event in our industry”, says Dr. Flannery.
The trial will entail a side-by-side comparison of two identically sized and outfitted cultivation containers using Dr. Robb Farms’ state-of-the-art hydroponics as the control and the AIS aeroponics system as the trial subject. Study objectives are: (a) verify AIS aeroponics system production yield of finished flower per light over one flower cycle, as compared to control; (b) verify water usage reduction, as compared to control; (c) verify nutrient efficiency due to a reduction in nutrient usage; and (d) verify flower quality parameters as compared to control.
The parties are now actively preparing for the initiation of the trial and expect to complete it by the fall of 2020. In the event that trial endpoints are achieved, Dr. Flannery will author a white paper at the conclusion of the trial.
For more information:
Aero Bloom
5405 Alton Pkwy #505
Irvine, CA 92604
[email protected]
aerobloom.com